Is Your Allergy Treatment Up-to-Date? What Italian Allergists Say About Mite Allergy
"Discover the latest trends and gaps in how Italian allergists prescribe and manage allergen immunotherapy for house dust mites."
House dust mite (HDM) allergies are a widespread issue, significantly impacting the quality of life for many. If you're among those constantly battling nasal congestion, itchy eyes, and disrupted sleep, you're likely seeking the most effective and up-to-date solutions.
Allergen immunotherapy (AIT) stands out as a potential game-changer, offering not just symptom relief but a chance to modify the course of the allergy itself. But how are allergists using this treatment in the real world? Are they leveraging the latest diagnostic tools and treatment approaches to provide the best possible care?
A recent survey of Italian allergists specializing in mite allergies provides valuable insights into current practices, revealing both areas of confidence and gaps in knowledge. Let's explore what this means for how mite allergies are diagnosed and treated.
Mite Allergy and Immunotherapy
House dust mite (HDM) sensitization can contribute to allergic rhinoconjunctivitis and allergic asthma. Allergen immunotherapy (AIT) aims to build immunotolerance to allergens and is described as a promising approach with the potential for long-term efficacy. Another source characterizes AIT as the only disease-modifying treatment for allergic rhinitis and asthma associated with HDM sensitization. The listed sources provide no prevalence figures for this subsection.
AIT as an Add-On Treatment
House dust mite is described as a predominant indoor aeroallergen worldwide and is associated with allergic rhinoconjunctivitis, allergic asthma, atopic eczema, and other allergic skin diseases. The European Academy of Allergy and Clinical Immunology (EAACI) developed an evidence-based guideline recommending HDM allergen immunotherapy as add-on treatment for HDM-driven allergic asthma. A listed review describes specific immunotherapy studied alongside pharmacologic treatment and allergen avoidance in patients with asthma associated with house dust mite allergy. The provided source material does not specify particular limitations or compare treatment methods.
Debates About Dust Allergen Origins
The historical account describes a researcher who concluded that mite species, despite being potent allergen sources, were not the origin of house-dust allergen. He nevertheless believed the allergen had a biological source and was skeptical of the alternative hypothesis that biochemical degradation in dust produced its allergenicity. A separate listed source presents a timeline of dust mite discoveries and their relevance to allergy and asthma research, but the supplied snippet does not name specific milestones or dates.
Key Findings: Where Allergists Agree (and Disagree)
The survey, presented at a meeting on allergen immunotherapy, captured the perspectives of 45 Italian allergists experienced in prescribing AIT. The allergists showed agreement on several key aspects of AIT, but divergences remain on others. Let's unpack the details:
- Continuous Treatment: There's a strong consensus that AIT should be an ongoing, continuous treatment.
- Tablet Acceptance: Lyophilized tablet formulations of AIT are generally well-received by patients.
- Fast Action: Many allergists find that AIT tablets provide noticeable relief within 3-6 months.
- Symptom and Medication Scoring: A combined assessment of symptom severity and medication use is a common practice for tracking treatment effectiveness.
Limited Specialist Follow-Up
A review on tablet allergen immunotherapy reports that, in common practice, patients with allergic rhinitis usually have a specialized visit once or twice per year at most. The supplied source snippet does not provide further details about management between visits or the effects of this visit frequency.
Variation in Reported Treatment Effects
An evidence-based analysis reports that meta-analyses and reviews find both subcutaneous allergen immunotherapy (SCIT) and sublingual allergen immunotherapy (SLIT) beneficial for house dust mite-induced allergic rhinitis and allergic asthma. It also notes that reported effect sizes vary greatly from one study to another. A separate 2025 source states that HDM sensitization is observed in approximately 50% of patients with asthma and estimates that HDM cause allergic symptoms in at least 1%–2% of the global population.
Developing HDM Immunotherapy Options
A 2022 review describes allergen immunotherapy as a promising treatment that has developed over recent decades and notes that modified HDM allergens have been developed to improve efficacy. It reports that clinical trials have shown significant therapeutic effects, without specifying the products or effect sizes in the supplied snippet. A separate 2026 page describes three choices—sublingual tablets, sublingual multi-allergen drops, and subcutaneous shots—but its supplied text does not provide comparative outcome data.
The Future of Mite Allergy Treatment: What This Means for You
This survey highlights the evolving landscape of mite allergy management. While AIT is recognized as a valuable tool, the inconsistencies in diagnostic approaches and treatment strategies underscore the need for ongoing education and standardization.
Market Research and Treatment Categories
A market research report published August 24, 2026, organizes the house dust mite allergy treatment market by treatment type, including oral medications, nasal sprays, eyedrops, and immunotherapy. It also segments the market by allergen exposure, severity, and region. Another listed report describes a sublingual tablet as immunotherapy placed under the tongue, where it dissolves and delivers small doses of the allergen. The supplied material does not include market-size figures or forecasts.
Global Burden and Disease Progression
A 2023 review estimates that house dust mite allergy affects approximately 65–130 million people worldwide. It warns that untreated HDM allergy may lead to severe disease manifestations, including atopic dermatitis or asthma. The same review says diagnosis and immunotherapy are well established but are often hampered by the use of mite extracts; the supplied snippet does not elaborate on the specific problems with those extracts.
Italian Allergists’ Prescribing Practices
A real-world survey examined how a group of Italian allergists prescribed allergen immunotherapy for house dust mite allergy. Its outcomes were discussed at the meeting “Clinical Evidence, Extracts Quality and Biotechnology Innovation in Allergen Immunotherapy,” held in Trieste, Italy, on October 1, 2017. The supplied source material does not report the survey’s specific findings.
The rise of molecular allergy diagnostics promises more precise and personalized treatment plans. As allergists increasingly adopt these advanced tools, patients can expect more targeted therapies and better outcomes. The convenience and acceptance of AIT tablets also point toward a more patient-friendly approach to long-term allergy management.
Ultimately, effective mite allergy treatment hinges on a collaborative approach. By staying informed about the latest advancements and actively engaging with your allergist, you can chart a course toward lasting relief and improved quality of life.